Blood Pressure Control Linked to Improved Survival in Metastatic Breast Cancer
Women diagnosed with metastatic breast cancer often grapple with multiple chronic health conditions, and hypertension, or high blood pressure, is a particularly common one. Recent research highlights the critical importance of managing blood pressure in this patient population, demonstrating a strong link between effective hypertension control and improved survival rates.
Hypertension Prevalence in Metastatic Breast Cancer
Nearly half of women with metastatic breast cancer have hypertension at diagnosis, with disproportionately higher rates observed among Black and Hispanic patients. This underscores existing disparities in cancer outcomes and the need for targeted interventions.
Polytherapy Improves Outcomes
A study published in 2026 revealed that using multiple classes of antihypertensive medications – known as polytherapy – is associated with significantly better survival outcomes compared to using a single medication (monotherapy). Specifically, polytherapy was linked to a 38% lower risk of all-cause mortality. [Source: Oncology Nurse Advisor]
Medication Adherence is Key
The benefits of hypertension management are further amplified by consistent medication adherence. Women who consistently filled their prescriptions experienced a 58% reduction in the risk of dying. [Source: Oncology Nurse Advisor] Polytherapy also proved more effective in achieving blood pressure control, with over 75% of patients reaching a systolic blood pressure below 140 mmHg during follow-up.
Disparities and the Importance of Coordinated Care
Research indicates that Black and Asian women with breast cancer are at a greater risk of cardiovascular disease (CVD) and cardiometabolic risk factors following a diagnosis of invasive breast cancer. [Source: Oncology Nurse Advisor] Black women, in particular, experience the most increased risks, including higher rates of hypertension, diabetes, ischemic heart disease, heart failure, and overall CVD compared to non-Hispanic White women. [Source: Oncology Nurse Advisor]
These findings emphasize the need for coordinated care involving oncologists, cardiologists, and primary care physicians. Prioritizing hypertension control as an integral part of survivorship care, alongside metastatic breast cancer treatment, may help extend life, especially for women of color who have historically faced disparities in cancer outcomes.
Future Research
Ongoing research will focus on identifying optimal antihypertensive regimens and developing integrated care models to further reduce disparities and improve outcomes for women with metastatic breast cancer and coexisting hypertension.
“These patients face an overwhelming burden of chronic conditions, yet these issues are often overlooked in the rush to treat the cancer itself. Our findings highlight a simple but powerful message: paying close attention to comorbidities may help extend life, especially for women of color who have long faced disparities in cancer outcomes,” says Reina Haque, PhD, MPH, lead researcher at Kaiser Permanente Southern California Department of Research & Evaluation.